Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181838 | 0.95 | NPC1 (0.73) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21100591 | 0.93 | MAPT (0.73) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31357491 | 0.92 | MAPT (0.78) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Methoxymethane SCHEMBL27278268 | 0.87 | MAPT (0.73) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6746981 | 0.87 | POLB (0.68) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31357499 | 0.87 | POLB (0.68) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31357494 | 0.86 | MAPT (0.70) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10486772 | 0.86 | MAPT (0.66) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1068092 | 0.85 | MAPT (0.69) | MAPTNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL9786970 | 0.85 | MAPT (0.74) | MAPTNPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116212919-B | CdS/g-C3N4Nanosheet composite material and preparation method and application thereof | 广西民族大学 | 2024-08-27 | — | — | CN | claimed |
| CN-116159578-A | Iron catalyst for catalyzing oxidative cleavage of lignin model to produce phenol and ester and application thereof | 天津理工大学 | 2023-05-26 | — | — | CN | claimed |
| CN-115697053-A | Biocide composition | 巴斯夫欧洲公司 | 2023-02-03 | — | — | CN | claimed |
| CN-118724726-A | Method for converting lignin and model compound thereof into primary benzylamine and phenolic compound | 中国科学院化学研究所 | 2024-10-01 | — | — | CN | disclosed |
| CN-116212919-B | CdS/g-C3N4Nanosheet composite material and preparation method and application thereof | 广西民族大学 | 2024-08-27 | — | — | CN | disclosed |
| CN-118255649-A | Samarium diiodide mediated lignin beta-O-4 ketone model compound free radical cleavage | 浙江大学 | 2024-06-28 | — | — | CN | disclosed |
| CN-116375641-A | C3-phenoxy substituted quinoline compound and synthetic method and application thereof | 杭州师范大学 | 2023-07-04 | — | — | CN | disclosed |
| CN-116212919-A | CdS/g-C 3 N 4 Nanosheet composite material and preparation method and application thereof | 广西民族大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-116159578-A | Iron catalyst for catalyzing oxidative cleavage of lignin model to produce phenol and ester and application thereof | 天津理工大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-109836311-B | Method for controlling lignin model molecule fracture by amine at room temperature | 中国科学院大连化学物理研究所 | 2022-05-06 | — | — | CN | disclosed |
| CN-114008832-A | Method for extinguishing an electrochemical generator in the event of thermal runaway | 原子能和替代能源委员会 | 2022-02-01 | — | — | CN | disclosed |
| US-6576643-B2 | Compounds containing dibenzo(A,D)cycloheptene or dibenz(B,F)oxepine derivatives are useful for treating osteoporosis, cardiovascular diosrders, cancer and inflammation | SMITHKLINE BEECHAM CORPORATION | 2003-06-10 | — | — | US | disclosed |
| US-20020091264-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-07-11 | — | — | US | disclosed |
| EP-1025090-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1025090-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999015508-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091264-A1 | Vitronectin receptor antagonists | CALCR, ADGRF1, CALCRL | MAPT 3004/4885NPC1 1061/4885RAB9A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.